Kidney Diseases, Chronic
7
2
2
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.4% vs benchmark
29%
2 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (7)
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Anrikefon vs Nalfurafine for Sleep Quality in Hemodialysis Patients With CKD-aP
Rutgers University Study of the Genetics of Kidney Disease
The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia
The Effect Of Mobile Traınıng Applıcatıons On Chronıc Renal Faılure Progressıon
A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients
Metabolomics for Identifying Biomarkers of Dietary Intake and Kidney Disease Progression